$784.61
0.34% day before yesterday
Nasdaq, Nov 26, 11:18 pm CET
ISIN
US75886F1075
Symbol
REGN

Regeneron Pharmaceuticals Stock price

$784.61
+199.30 34.05% 1M
+196.27 33.36% 6M
+72.28 10.15% YTD
+31.58 4.19% 1Y
+43.13 5.82% 3Y
+276.30 54.36% 5Y
+222.92 39.69% 10Y
+773.87 7,205.49% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
-2.71 0.34%
ISIN
US75886F1075
Symbol
REGN
Industry

New AI Insights on Regeneron Pharmaceuticals Insights AI Insights on Regeneron Pharmaceuticals

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$82.5b
Enterprise Value
$76.7b
Net debt
positive
Cash
$8.4b
Shares outstanding
105.3m
Valuation (TTM | estimate)
P/E
18.4 | 18.4
P/S
5.8 | 5.7
EV/Sales
5.4 | 5.3
EV/FCF
19.8
P/B
2.7
Dividends
DPS
$3.52
Yield 1Y | 5Y
0.5% | 0.1%
Growth 1Y | 5Y
100.0% | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
1 Year
Financials (TTM | estimate)
Revenue
$14.2b | $14.4b
EBITDA
$4.5b | $4.6b
EBIT
$3.9b | $4.4b
Net Income
$4.6b | $4.5b
Free Cash Flow
$3.9b
Growth (TTM | estimate)
Revenue
2.9% | 1.3%
EBITDA
-4.4% | -2.7%
EBIT
-6.2% | 3.7%
Net Income
-1.6% | 2.0%
Free Cash Flow
16.9%
Margin (TTM | estimate)
Gross
86.3%
EBITDA
31.3% | 31.8%
EBIT
27.6%
Net
32.1% | 31.3%
Free Cash Flow
27.2%
Financial Health
Equity Ratio
77.7%
Return on Equity
15.0%
ROCE
11.0%
ROIC
11.6%
Debt/Equity
0.1
More
EPS
$42.7
FCF per Share
$36.9
Short interest
2.9%
Employees
15k
Rev per Employee
$940.0k
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Regeneron Pharmaceuticals forecast:

26x Buy
76%
7x Hold
21%
1x Sell
3%

Analyst Opinions

34 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
76%
Hold
21%
Sell
3%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
14,248 14,248
3% 3%
100%
- Direct Costs 1,955 1,955
7% 7%
14%
12,293 12,293
2% 2%
86%
- Selling and Administrative Expenses 3,197 3,197
10% 10%
22%
- Research and Development Expense 5,157 5,157
5% 5%
36%
4,459 4,459
4% 4%
31%
- Depreciation and Amortization 525 525
12% 12%
4%
EBIT (Operating Income) EBIT 3,934 3,934
6% 6%
28%
Net Profit 4,578 4,578
2% 2%
32%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Neutral
GlobeNewsWire
3 days ago
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now ...
Neutral
GlobeNewsWire
3 days ago
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Neutral
24/7 Wall Street
4 days ago
The shortened holiday week is here, and the futures are trading higher this morning.
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 15,158
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today